Advances in conventional cancer therapy have not produced any significant improvement in the treatment of glioblastoma multiforme (GBM). Therefore, the further development of novel treatment modalities for GBM, such as boron neutron capture therapy (BNCT), remains a pressing task for the health science community in the USA. Subject of the present grant application is the continued development of 3-carboranyl thymidine analogues (3CTAs), a novel class of BNCT agents for the treatment of GBM. The mechanism of action of 3CTAs is primarily based on their ability to function as substrates of human thymidine kinase 1 (TK1), which is only active in proliferating cells. BNCT of tumor-bearing rodents that had received N5-2OH, the current lead compound of our 3CTA library, via intracerebral (i.c.) or intratumoral (i.t.) injection resulted in reduced tumor growth and prolonged survival times. On the other hand, the same studies have revealed two major limitations of N5-2OH and other 3CTAs. These are (1) the suboptimal competition with endogenous thymidine (Thd) at the substrate-binding site of TK1 and (2) the lack of water-solubility, which necessitated the use of organic solvents to solubilize 3CTAs for biological studies. In addition crucial biochemical and biological features of 3CTAs are still unknown. These are (3) the anabolism of 3CTAs beyond the monophosphorylation step, including their possible incorporation into DNA, and (4) the mechanisms that 3CTAs and their metabolites recruit to enter and exit cells. To address these shortcomings, the following SPECIFIC AIMS were developed: (1) To synthesize 3CTAs with improved ability to compete with Thd at the active site of TK1, to evaluate their substrate and inhibitory capacities in enzyme assays with TK1, and to determine their physicochemical properties, (2) to synthesize water-soluble amino acid prodrugs of N5-2OH and to evaluate their applicability for i.c. administration, (3) To study the metabolism of N5-2OH and 3CTAs with improved drug-like and enzymatic properties that emerged from Specific Aims 1 and 2 in vitro and in enzyme assays with nucleotide kinases and DNA polymerase, (4) to study the mechanisms of cellular influx and efflux of N5-2OH, 3CTAs with improved drug-like and enzymatic properties that emerged from Specific Aims 1 and 2, and their metabolites in vitro, and (5) to optimize parameters for i.c. administration of the 3CTA with the most improved drug-like and enzymatic properties that emerged from Specific Aims 1- 4 to RG2 glioma bearing rats and to determine possible neurotoxicity.

Public Health Relevance

Novel boronated nucleosides will be developed for the treatment of brain tumors by boron neutron capture therapy (BNCT). BNCT is a binary treatment modality for cancer that relies both on a chemical and a radiation component. Brain tumors called glioblastoma multiforme are among the deadliest of all cancers. Advances in conventional cancer therapy have not produced any significant improvement in the treatment of these brain tumors. BNCT of these brain tumors with boronated nucleosides may have the potential to improve survival rates.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ONC-P (02))
Program Officer
Capala, Jacek
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Other Health Professions
Schools of Pharmacy
United States
Zip Code
Barth, Rolf F; Yang, Weilian; Nakkula, Robin J et al. (2015) Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors. Appl Radiat Isot 106:251-5
Agarwal, Hitesh K; Khalil, Ahmed; Ishita, Keisuke et al. (2015) Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer. Eur J Med Chem 100:197-209
Khalil, Ahmed; Ishita, Keisuke; Ali, Tehane et al. (2014) Iodine monochloride facilitated deglycosylation, anomerization, and isomerization of 3-substituted thymidine analogues. Nucleosides Nucleotides Nucleic Acids 33:786-99
Khalil, Ahmed; Ishita, Keisuke; Ali, Tehane et al. (2013) N3-substituted thymidine bioconjugates for cancer therapy and imaging. Future Med Chem 5:677-92
Agarwal, Hitesh K; McElroy, Craig A; Sjuvarsson, Elena et al. (2013) Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1. Eur J Med Chem 60:456-68
Sjuvarsson, Elena; Damaraju, Vijaya L; Mowles, Delores et al. (2013) Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy. J Pharmacol Exp Ther 347:388-97
Hasabelnaby, Sherifa; Goudah, Ayman; Agarwal, Hitesh K et al. (2012) Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors. Eur J Med Chem 55:325-34
Tiwari, Rohit; Toppino, Antonio; Agarwal, Hitesh K et al. (2012) Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues. Inorg Chem 51:629-39
Agarwal, Hitesh K; Buszek, Benjamin; Ricks, Kevin G et al. (2011) Synthesis of Closo-1,7-Carboranyl Alkyl Amines. Tetrahedron Lett 52:5664-5667
Tiwari, Rohit; Mahasenan, Kiran; Pavlovicz, Ryan et al. (2009) Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, FlexX, Glide, and Surflex. J Chem Inf Model 49:1581-9